Compare RVYL & HKPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RVYL | HKPD |
|---|---|---|
| Founded | 2007 | 2016 |
| Country | United States | Hong Kong |
| Employees | N/A | 27 |
| Industry | Professional Services | Other Pharmaceuticals |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 6.9M |
| IPO Year | 2008 | N/A |
| Metric | RVYL | HKPD |
|---|---|---|
| Price | $7.81 | $0.43 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 44.1K | ★ 408.9K |
| Earning Date | 04-15-2026 | 08-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,131,000.00 | N/A |
| Revenue This Year | $770.54 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.14 | $0.32 |
| 52 Week High | $8.55 | $2.58 |
| Indicator | RVYL | HKPD |
|---|---|---|
| Relative Strength Index (RSI) | 67.46 | 38.04 |
| Support Level | $5.00 | $0.37 |
| Resistance Level | $8.55 | $0.71 |
| Average True Range (ATR) | 0.65 | 0.06 |
| MACD | 0.11 | -0.01 |
| Stochastic Oscillator | 96.06 | 42.66 |
Ryvyl Inc is a financial technology company that provides payment acceptance and disbursement solutions, mainly enabling merchants to process credit card transactions through BIN sponsorship arrangements with acquiring banks and payment processors, where it operates as an intermediary performing functions such as merchant underwriting, onboarding, risk monitoring, and customer support. The company also offers its internally developed NEMS Core platform, which facilitates automated inbound and outbound disbursements through a modular workflow system.
Cellyan Biotechnology Co Ltd formerly, Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.